Diagnosis and Treatment of Plasmodium vivax Malaria - Advances in Parasitology - page 267

Tjitra, E., Baker, J., Suprianto, S., Cheng, Q., Anstey, N.M., 2002. Therapeutic efficacies of
artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in
vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob.
Agents Chemother. 46, 3947-3953.
Tjitra, E., Anstey, N.M., Sugiarto, P., Warikar, W., Kenangalem, E., et al., 2008. Multidrug-
resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in
Papua, Indonesia. PLoS Med. 5, 6.
Torres, J.R., Perez, H., Postigo, M.M., Silva, J.R., 1997. Acute non-cardiogenic lung injury in
benign tertian malaria. Lancet 350, 31-32.
Udomsangpetch, R., Somsri, S., Panichakul, T., Chotivanich, K., Sirichaisinthop, J., et al.,
2007. Short-term in vitro culture of field isolates of Plasmodium vivax using umbilical
cord blood. Parasitol. Int. 56, 65-69.
Weiss, W.R., Oloo, A.J., Johnson, A., Koech, D., Hoffman, S.L., 1995. Daily prima-
quine is effective for prophylaxis against falciparum malaria in Kenya: comparison
with mef loquine, doxycycline, and chloroquine plus proguanil. J. Infect. Dis.
171, 1569-1575.
Wells, T.N., Burrows, J.N., Baird, J.K., 2010. Targeting the hypnozoite reservoir of Plasmodium
vivax : the hidden obstacle to malaria elimination. Trends Parasitol. 26, 145-151.
Whitby, M., Wood, G., Veenendaal, J.R., Rieckmann, K., 1989. Chloroquine-resistant Plas-
modium vivax . Lancet 2, 1395.
White, N.J., Olliaro, P.L., 1996. Strategies for the prevention of antimalarial drug resistance:
rationale for combination chemotherapy for malaria. Parasitol. Today 12, 399-401.
White, N.J., Stepniewska, K., Barnes, K., Price, R.N., Simpson, J., 2008. Simplified antima-
larial therapeutic monitoring: using the day-7 drug level?. Trends Parasitol. 24, 159-163.
White, N., 1999. Antimalarial drug resistance and combination chemotherapy. Philos. Trans.
R. Soc. Lond. B Biol. Sci. 354, 739-749.
White, N.J., 2008. How antimalarial drug resistance affects post-treatment prophylaxis.
Malar. J. 7, 9.
White, N.J., 2011. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar.
J. 10, 297.
Whitty, C.J., Chandler, C., Ansah, E., Leslie, T., Staedke, S.G., 2008. Deployment of
ACT antimalarials for treatment of malaria: challenges and opportunities. Malar. J.
7 (Suppl. 1), S7.
WHO Global Malaria Programme, 2009. Malaria Rapid Diagnostic Test performance. Sum-
mary results of WHO product testing of malaria RDTs: Round 1 and 2 (2008-2009).
Available: http://www2wprowhoint/NR/rdonlyres/E4823BBF-69FC-45DE-B924-
1A9FCDD7406C/0/RoundIII_SummaryFINALpdf .
Wilson, M.E., Weld, L.H., Boggild, A., Keystone, J.S., Kain, K.C., et al., 2007. Fever in
returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis
44, 1560-1568.
Wiselogle, F.Y., 1946. A Survey of Antimalarial Drug, 1941-1945. Michigan, Ann Arbor.
World Health Organization, 2009a. Malaria microscopy quality assurance manual. Version
1. 125 p.
World Health Organization, 2009b. World Malaria Report 2009. 1-66.
World Health Organization, 2010. Guidelines for the Treatment of Malaria, Second ed. WC
770: 191 p.
World Health Organization, 2012. WHO Global Malaria Programme: Information Note on
Recommended Selection Criteria for Procurement of Malaria Rapid Diagnostic Tests
(RDTs). WHO 12 April 2012. Available at: http://wwwwhoint/malaria/diagnosis_
treatment/diagnosis/RDT_selection_criteriapdf .
Yadav, R.S., Ghosh, S.K., 2002. Radical curative efficacy of five-day regimen of primaquine
for treatment of Plasmodium vivax malaria in India. J. Parasitol. 88, 1042-1044.